Alkem Labs Q2 FY26: Revenue at Rs 40,010 mn, PAT Rs 7,791 mn; H1 revenue up 14%

Exceptional itemResults restatedResults View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹5770.00

prior close

₹5844.00

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.8% vs market

Pharmaceuticals peers, median of 157sector-0.0%-1.1% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-1.0

15m

-1.4

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.3-0.8-0.0-1.1

Next day

-0.9-0.3-0.6-0.4-0.4

-0.8+0.4-1.2-0.3-0.4

-1.0-0.2-0.8-1.1+0.1

-0.5+0.1-0.6-1.4+0.9

-1.5+0.1-1.5-1.6+0.1

-2.8-1.4-1.4-3.3+0.5

15d

-2.3-1.2-1.1-3.4+1.1

-2.8-1.2-1.6-4.3+1.5

+1.6-2.1+3.8-6.9+8.5

-6.4-2.3-4.1-8.8+2.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Labs Q2 FY26 consolidated revenue at Rs 40,010 million, up 17% YoY; PAT at Rs 7,791 million, up 11% YoY. H1 FY26 revenue grew 14% to Rs 73,721 million; PAT up 15% to Rs 14,470 million. Standalone H1 revenue rose 9% to Rs 49,142 million. Exceptional gain of Rs 142.9 million from Indore facility sale. Generic business transferred to subsidiary Alkem Wellness as discontinued ops from October 1, 2025. Auditor issued unmodified review report.

Likely market impact

Solid YoY revenue and profit growth, one-time exceptional gain from Indore sale; generic business moved to discontinued ops. Net readout is positive.